Abstract
Methods Observational study to analyse immune and virological response, and incidence of adverse events during raltegravir therapy. Transaminase elevation(TE) was scored according to increase in ALT value 2.6–5× upper normal limit (toxicity grade 2), 5.1–10× upper normal limit (toxicity grade 3) and >10× upper normal limit (toxicity grade 4). To avoid bias related to patients with high baseline serum ALT and AST levels, TE was defined by increase in ALT value 2.6–3.5× (toxicity grade 2), 3.6–5× (toxicity grade 3), and >5× (toxicity grade 4) the baseline value. Metabolic and renal profile were assessed at baseline, after 1 month and every 3 months. 103 HIV+ patients have been enrolled; 37 patients were HCV or HBV co-infected. CDC group was 50C, 34B and 19A. Previous therapeutic mean lines was 9.1; mean mutations were 5.5 for NRTI and 8.6 for PI.
Highlights
Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
To avoid bias related to patients with high baseline serum ALT and AST levels, TE was defined by increase in ALT value 2.6–3.5×, 3.6–5×, and >5× the baseline value
Total cholesterol showed a statistically significant increase (p = 0.0115 and p = 0.0442) at 3 (196 mg/dl) and 6 (189 mg/ dl) months, probably due to boosted protease inhibitor association; 48 patients had at baseline cholesterol values in the upper normal limit and the lipid profile did not worsen during follow-up
Summary
Address: 1Sacco Hospital II Dept Inf Disease, Milan, Italy and 2Sacco Hospital I Dept Inf Disease, Milan, Italy * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. 9–13 November 2008. Address: 1Sacco Hospital II Dept Inf Disease, Milan, Italy and 2Sacco Hospital I Dept Inf Disease, Milan, Italy * Corresponding author from Ninth International Congress on Drug Therapy in HIV Infection Glasgow, UK. Published: 10 November 2008 Journal of the International AIDS Society 2008, 11(Suppl 1):P31 doi:10.1186/1758-2652-11-S1-P31. Abstracts of the Ninth International Congress on Drug Therapy in HIV Infection Meeting abstracts – A single PDF containing all abstracts in this Supplement is available here. http://www.biomedcentral.com/content/pdf/1758-2652-11-S1-info.pdf
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
